Quanterix (NASDAQ:QTRX – Get Free Report) and StageZero Life Sciences (OTCMKTS:GNWSF – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
Insider & Institutional Ownership
86.5% of Quanterix shares are held by institutional investors. Comparatively, 0.0% of StageZero Life Sciences shares are held by institutional investors. 1.5% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Quanterix and StageZero Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quanterix | $138.90 million | 0.99 | -$107.15 million | ($2.63) | -1.11 |
| StageZero Life Sciences | $4.15 million | 0.02 | -$6.86 million | ($0.28) | -0.00 |
StageZero Life Sciences has lower revenue, but higher earnings than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than StageZero Life Sciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Quanterix has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, StageZero Life Sciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Quanterix and StageZero Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
| StageZero Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
Quanterix presently has a consensus target price of $3.00, suggesting a potential upside of 2.74%. Given Quanterix’s stronger consensus rating and higher probable upside, equities analysts clearly believe Quanterix is more favorable than StageZero Life Sciences.
Profitability
This table compares Quanterix and StageZero Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quanterix | -80.25% | -26.09% | -19.03% |
| StageZero Life Sciences | -200.26% | N/A | -165.13% |
Summary
Quanterix beats StageZero Life Sciences on 9 of the 13 factors compared between the two stocks.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
About StageZero Life Sciences
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
